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ABSTRACT 
 
Cancer, the second leading cause of death in the US, is caused by mutations in select 
genes that alter cellular function leading to uncontrolled proliferation. Understanding the specific 
genes that drive cancer can lead to the generation of novel cancer therapies. To identify novel 
genes that drive cancer in the colon (CRC), lungs, and ovaries in mice, Starr et al. employed a 
transposon-based insertional mutagenesis system. One of the genes identified, APC, is mutated 
in 70-80% of human CRCs. CUL3, suspected to be a general driver gene, was discovered in the 
lung cancer screen. CUL3 was analyzed for its role in a human CRC cell line in this study. CUL3 
gene knockout was performed using the CRISPR/Cas9 system, which targets mutations to 
specific genes, thereby knocking out that gene’s function. Three different sites in the CUL3 gene 
were targeted for mutation and resulted in the creation of 41 separate cell lines with potential 
CUL3 knockout. Of those 41 cell lines, 25 exhibited qualitatively abnormal phenotypes 10 days 
after transfection. These phenotypes include slowed growth (25 of 25 cell lines), increased cell 
size (16 of 25 cell lines), and variation of cell adherence to culture flask surface (11 of 25 cell 
lines). Knockout was confirmed in 6 cell lines by using PCR in the region of the gene targeted 
for mutation and sequencing the PCR product. Each cell line was quantitatively evaluated for 
metabolic activity (or cell growth rate) using an MTS assay. If CUL3 knockout is shown to 
reduce overall cell growth and increase susceptibility to chemotherapy, this would support the 
development of new therapies for CRCs that target CUL3 function. 
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INTRODUCTION 
PROJECT SIGNIFICANCE 
Cancer is as pervasive as it is destructive. As the second leading cause of death in the US, 
it has become a ubiquitous danger in today’s society (Murphy et al. 2013). Colorectal cancer 
(cancer of either the colon or rectum) is the third most common cancer in both sexes, after 
breast/prostate and lung cancers. According to the American Cancer Society, in 2014 an 
estimated 96,830 new cases of colon cancer will be diagnosed, and 50,310 people are expected to 
die of this disease. In an individual’s lifetime, it is estimated that they will have a 1 in 20 chance 
of developing colorectal cancer. That’s 5% of the US population (American Cancer Society). 
Current colon cancer treatments include surgery, radiation therapies, and chemotherapy. 
Surgery is used to remove the portion of bowel that contains the tumor and is most the effective 
treatment at earlier stage cancers. Radiation therapies use high energy light rays to destroy the 
cancer cells. This is most commonly used when the tumor is in later stages and has invaded 
another internal organ or abdomen lining, where surgery would be more difficult. It is also 
commonly used when the cancer has spread, especially when it has spread to the bones or brain, 
sites that are inoperable. Chemotherapy is the administration of drugs designed to kill quickly 
dividing cells. In colorectal cancer, chemotherapy is mainly administered to patients post-surgery 
to rid the body of any remaining tumor cells, as well as to those in advanced stages to lengthen 
life-expectancy (American Cancer Society). These particular chemotherapies include standard 
rapid growth inhibitors, like capecitabine (the first line treatment) and irinotecan (a second line 
treatment), which inhibit RNA synthesis and DNA replication, respectively. They also include 
monoclonal antibodies, which target epidermal growth factor receptors (EGFRs), often 
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overexpressed in colorectal cancer, but which are only effective in cancers overexpressing 
EGFRs (Cortejoso & Lopez-Fernandez 2012).  
Depending on the stage, certain treatments are more effective. Stage I is almost 
exclusively treated with surgery, and has a 5 year survival rate of 74%. Stages II and III usually 
is a combination of treatments, with surgery when possible and radiation when not, as well as 
chemotherapy. Both of these stages range in survival rates (II: 37%-67%; III: 28%-73%) 
depending on the location of the tumor, the amount the tumor has invaded into other organs, and 
whether or not it has reached the lymph system. Stage IV is the most fatal, as the cancer has 
already spread to other organs and is often inoperable, which is why chemotherapy is often given 
to slow the growth of the cancer. The survival rate for this cancer is 6% (American Cancer 
Society).  
Cancer is the result of multiple mutations (about 5-10) in select genes that allow cells to 
rapidly divide and consume the body’s resources. These “driver” genes have often been reduced 
to oncogenes and tumor suppressors, where oncogenes gain function to induce tumorigenesis and 
tumor suppressors lose function to allow growth (Vogelstein & Kinzler 2004). However, with 
the boom of genetic study following the Human Genome Project, other classes of genes that 
affect tumorigenic growth have been identified. Hanahan and Weinberg have published more 
than one paper entitled Hallmarks of Cancer with the goal of classifying potential tumorigenic 
genes or cellular properties and widening our understanding of the genetic causes to cancer. In 
their latest edition, published in 2011, they add four more hallmarks, bringing the total to 10. 
These include, but are not limited to, properties that induce angiogenesis, increase genome 
instability, resist growth suppressors, and avoid immune response. By recognizing the driver 
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genes that allow tumorigenic growth, we can specifically target the effects of these genes to 
create swifter and more effective treatment.  
The most famous (and very effective) targeted cancer driver therapy is the drug 
Herceptin. It specifically interferes with the gene HER2, which is commonly mutated in breast 
cancer, as well as other cancers. The mutation results in the overexpression of the HER2 protein 
receptor on the outside of the cells that, when activated, signals the cell to start dividing. 
Herceptin interrupts this pathway by blocking the receptor so that the cell cannot receive the 
signal to divide. The drug has been shown to be extremely effective on late-stage and spreading 
cancers, helping those who would not benefit from more traditional therapies. (Herceptin).   
This research, like the Herceptin research, could be the stepping stone to creating more 
specific cancer drugs with fewer side effects. By knowing what genetic mutations help or hinder 
tumorigenesis, we may be able target those pathways to slow the cancer’s growth, giving patients 
more time and options. 
 
TRANSPOSON-BASED INSERTIONAL MUTAGENESIS 
Transposon-Based Insertional Mutagenesis 
 There are various ways to induce tumorigenesis in models to study cancer. Until recently 
retroviral insertional mutagenesis was the method of choice, as it allowed for rapid tumor 
induction and high throughput. However, this method is not truly random, as the proviral DNA 
has tendencies to integrate at the 5’ ends of genes. It can also affect the promotion of oncogenes 
hundreds of kilobases away by way of an enhancer within the proviral DNA, making it difficult 
to determine which gene the insertion is truly affecting (Copeland and Jenkins 2010). Since this 
method of tumorigenesis does not lend itself to accurate biostatistical analysis, another rapid, 
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high-throughput method was needed. It was found in transposon-based insertional mutagenesis 
(TIM).  
 DNA-only transposons are short segments of DNA that can move randomly within the 
genome. Traditionally, these transposons move on their own, coding for their own excision and 
integration enzyme, called a transposase, within the transposable element. However, non-
autonomous transposons have been experimentally created, and are able to be controlled by 
providing the transposase in trans, i.e. separate from the transposable element (Copeland and 
Jenkins 2010). Multiple copies of the transposon within the genome ensures high rates of 
mutative transposition, as there is a 30-40% chance that the transposon will not reintegrate after 
excision (Copeland and Jenkins 2010).  
 The Sleeping Beauty (SB) transposon is one of those that have been used to induce 
cancer in mice. It was originally seen in fish, xenopus, and even human genomes, however, 
generations of mutations left the transposase catalytically inactive. Ivics et al. (1997) 
reconstructed the transposase and “awoke” the transposon from evolutionary sleep, allowing its 
transposition to occur again. Its mobility in mammalian species made it an excellent candidate 
for alteration for research use.  
 
Figure 1. The layout of the T2/Onc2 transposon. The DNA-only transposon is capped with inverted repeats (the 
black arrows at the ends) and includes two splicing acceptor sites (SA) and a splicing donor site (SD); a murine stem 
cell virus (MCSV LTR) promoter; and a poly-adenine tail sequence (pA). 
 
 To utilize the SB transposon as a cancer inducer, Dupuy et al. created the T2/Onc2 
transposon (2005) (Figure 1). It contains a murine stem cell virus long terminal repeat (MSCV 
LTR) to activate transcription and a polyadenylation tail to signal the early termination of 
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transcription. Splice donor and splice acceptor sites are to alter the splicing of the mRNA product 
of the intended targets. Breeding the T2/Onc2 transgenic mice with another transgenic strain, 
known as RosaSB, which expressed the SB11 transposase ubiquitously in all tissues, led to 
double transgenic mice that have the ability to mobilize the T2/Onc2 transposon. Unfortunately 
(or fortunately) for Dupuy et al., the transposon/transposase combination worked too well – 
many transgenic mice died as embryos due to lethal mutations caused by the transposon system 
(2005). Of the 24 mice that survived weaning, all had died of cancer (mostly blood cancers) by 
17 weeks.  
Transposon Use for Discovery of CRC Driver Genes 
 In 2009, Dr. Starr and a team of researchers at the University of Minnesota published a 
paper that utilized TIM to create a murine model of colorectal cancer. They bred a line of 
transgenic mice from three others: RosaSB, VillinCre, and T2/Onc. The RosaSB and VillinCre 
mice were first bred together. The offspring from this mating had transposase expression that 
was exclusive to the epithelium of the colon. This double-transgenic mouse was then bred with 
the T2/Onc mouse to create the triple-transgenic line that contained the directed transposase and 
25 copies of the T2/Onc2 transposon. The mice were then watched for 18 months, or until they 
passed away from colorectal cancer at which time the tumors were then harvested and 
genotyped. The location of each transposon insertion was determined. Genomic analysis was 
performed on all insertion sites and a catalogue of driver versus passenger mutation was created 
based off of biostatistics on the likelihood of multiple insertions being randomly close together in 
the genome. Of the 135 tumors harvested, 16,690 insertion sites were catalogued. From thse 
insertion sites, 77 genes were found to be likely colorectal cancer driver genes.  
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 One gene of note discovered in this system was the APC gene. This gene is found in over 
70% of colorectal cancers and serves as a proof-of-concept discovery. While many of the genes 
identified have already been catalogued, many had not been previously linked to colorectal 
cancer.  
Dr. Starr has since repeated this process in lung and ovarian cancers in mice (Starr, 
unpublished). CUL3 was found to be a driver gene in lung cancers, though further study 
indicates that CUL3 may be a general cancer driver gene, and was hence used in this study to 
determine if it may have a role in CRC development. 
CUL3 FUNCTION AND ITS POTENTIAL ROLE IN CANCER 
Ubiquitination and Protein Degradation 
 Ubiquitination is the process of attaching the small protein, called ubiquitin, to a protein 
to affect its function. The attachment of ubiquitin to target proteins involves three mediating 
enzymes: ubiquitin-activating enzyme 
(E1), ubiquitin-conjugating enzyme (E2), 
and ubiquitin ligase (E3) (Figure 2). 
While there are few types of E1 and E2s, 
E3s are the most diverse group of 
ubiquitination enzymes, with over 500 E3 
ligases identified (Andérica-Romero et 
al. 2013). The more common process of 
polyubiquitination marks proteins for 
degradation, while monoubiquitination is 
Figure 2. Schematic of Ubiquitin Ligation. (Adapted from 
Andérica-Romero et al. 2013) Ubiquitination requires more than 
just the ligase. Above, the ligase uses an adapter to bind to the 
target protein. Nedd8 is a neddylation factor (see pg. 12) that 
alters ligase function, Ub is the ubiquitin, and E2 is the Ub-
conjugating enzyme.  
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occasionally used to alter the function of or localize certain proteins (less is known about 
monoubiquitination). 
Ubiquitin-dependent degradation is performed by the 26S proteasome complex. The 
complex is a conglomeration of proteases that create a cylindrical tube of catalytic activity, 
capped by a regulatory “lid” that protects cytosolic proteins from accidentally entering the 
catalytic cylinder. The proteasome lid recognizes the ubiquitin and unwinds the target protein, 
feeding it through the cylinder, where the protein is degraded into short peptides for reuse 
(Voges et al. 1999). The complex is ATP-dependent and responsible for 80-90% of cellular 
protein degradation (Thompson et al. 2008, Voges et al. 1999). While ubiquitination has long 
been associated with apoptosis, the process is also integral in cell-fate specification, 
transcription, and cell cycle progression. 
CUL3 Ubiquitination 
CUL3 is a gene located on chromosome 2 in the human genome, and the gene of interest 
for this study. It codes for the cullin 3 protein, which has a major role in polyubiquitination. 
Cullin 3 falls into the more common class of ubiquitin ligases, the cullins. The cullins are often 
referred to as CRLs, or cullin-RING ubiquitin ligases. Ubiquitination by way of CUL ligase is 
not exclusive to one protein, or even a family of proteins. It has many different substrates at 
many different stages of life. As a result, issues with CUL3 affects a cascade of different proteins 
and cellular processes. A few substrates of the ligase are well known, but many more are 
probably yet to be discovered (Andérica-Romero et al. 2013). 
One known CUL3 ligand is the MEI1 protein involved in cell division. This particular 
protein is used in gamete formation primarily, as it signals the formation of a meiotic spindle. 
However, its creation and subsequent degradation is also required for the functional assembly of 
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a mitotic spindle (Pintard et al. 
2004). Without CUL3 
polyubiquitination and 
degradation, the mitotic spindle 
will form much more similarly to 
a meiotic spindle, where the 
spindle is formed on one side of 
the cell and uneven cleavage 
along the divisional plane occurs (Pintard et al. 2004). The result is two unequally sized daughter 
cells (Figure 3). Unfortunately, nearly all data surrounding inquiry into this protein comes from 
Caenorhabditis elegans zygotes, though there is a human homolog.  
 CUL3 also targets Nrf2 (Nuclear-factor erythroid-derived-2-like 2), a transcription factor 
involved in the response to oxidative stress. During homeostasis, Nrf2 is constantly bound to 
KEAP1, an adapter protein that facilitates CUL3 targeting (Zhang et al. 2004A) Nrf2 is then 
ubiquitinated and degraded by the 26S proteasome. This process of rapid creation and 
degradation (turnover of about 20 minutes) continues until the cell undergoes oxidative stress, 
after which Nrf2 is allowed to aid in the transcription of many different proteins that respond to 
such a stress (Kobayashi et al. 2004; Zhang et al. 2004A). Overexpression of Nrf2 has been seen 
to aid in glioma resistance to the chemotherapy carmustine, though these results are only seen in 
neurological and immune cell cancers as these are the only cancers in which carmustine is used 
(Sukumari-Ramesh et al. 2015). In gastric cancers, Nrf2 expression has been directly correlated 
with cancer aggressiveness (Kawasaki et al. 2015).   
Figure 3. Effects of CUL3 knockout on mitotic spindle formation. (Pintard 
et al. 2004; Used with permissions from Wiley Online Library) CUL3 
knockout eliminated MEI1 degradation from the cell cycle, allowing the 
mitotic spindle to form more similarly to the meiotic spindle. 
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 Another target for CUL3 ligase proteasome degradation is the topoisomerase I protein, a 
complex that releases torsional stress on DNA during replication. Topoisomerase I (TOP1) is the 
main target of camptothecin (CPT)-type chemotherapies, two of which (topotecan and 
irinotecan) are currently FDA-approved. A knockout in CUL3 should increase the amount of 
TOP1 in the cell as there is no degradation machinery available to eliminate it. In fact, 
overexpression of CUL3 has been shown to induce resistance to CPT chemotherapies by way of 
down-regulation of TOP1, the target of CPTs (Zhang et al. 2004B, Beretta et al. 2013).  
CUL3 has also been recently 
implicated in having a role in mitotic 
spindle stability and localization of 
chromosomes during anaphase. 
However, CUL3 does this through 
monoubiquitination (a process that has 
only two known CUL3 substrates) rather 
than polyubiquitination. This single 
ubiquitin is not enough to signal for 
proteasomal degradation, but instead 
simply alters protein function (Maerki et 
al. 2010). The target is Aurora B kinase, a component of the Chromosomal Passenger Complex 
(CPC). The CPC localizes to chromosomes at the beginning of mitosis and to the spindle 
microtubules as anaphase begins to ensure proper cytokinesis (Maerki et al. 2009, 2010). 
Monoubiquitination is critical for localization to the spindle. It has been suggested that 
ubiquitination allows Aurora B and the CPC to bind to the microtubules by way of an ubiquitin 
Figure 4. Abnormal microtubule formation with Aurora B 
kinase inhibition. (Kallio et al. 2002; Used with permissions 
from Elsevier) Anti-Aurora B antibody injection results in 
abnormal microtubule formation and mis-localized 
chromosomes. The yellow arrow shows at least one 
chromosome off of the divisional plane. The white arrows 
point to centrosome location. 
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binding domain (UBD) within one of the associated microtubule proteins (Maerki et al. 2010). 
Additionally, there is evidence that ubiquitination allows dissociation from mitotic chromosomes 
in the first place to allow secondary localization (Sumara et al. 2007). Localization is critical to 
properly cleave the cells, and failure to localize results in multinucleated cells (Maerki et al. 
2009). Additionally, there is evidence that Aurora B inhibition results in more astral microtubule 
formation (deriving from the centrosome but not connecting to a kinetochore) and more fragile 
spindles in general (Kallio et al. 2002) (Figure 4). It should be noted that, unlike other substrates 
of CUL3 where knockout would result in their overexpression, CUL3 knockout effectively 
knocks out Aurora B function. 
 Notably, CUL3 has also been implicated in cyclin E degradation (Singer et al. 1999). 
Cyclin E is responsible for cell cycle control. Its attachment to Cdk2 (cyclin-dependent kinase) 
regulates cell cycle transitions (Hwang & Clurman 2005). The amount of free cyclin E during 
cell cycle transitions, which is often used as an indicator of Cdk2 activity, has best been 
characterized at the exit of G1 and the duration of S phase. Increased cyclin E expression is often 
the herald of the end of G1, often working in tandem with other mitogenic signals (Singer et al. 
1999). Additionally, its abundance during S phase is inversely correlated with the duration of S 
phase (Hwang & Clurman 2005). CUL3 targets cyclin E in its unbound form, but if the 
ubiquitination process is interrupted, by CUL3 knockout or 26S proteasome inhibition, the cell 
cycle timing becomes disrupted. G1 is much shorter due to the abundance of cyclin E. The cells 
also spend more time in S phase than a normal cell (Singer et al. 1999, Hwang & Clurman 2005). 
 In addition to changes in duration of the cycle phases, there is also evidence that up-
regulation of cyclin E results in more genetic instability. This implies that expression of cyclin E 
may increase the mutagenic and oncogenic properties of any given cell. It also gives some 
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interesting clinical applications as well. Many studies reviewed by Hwang and Clurman (2005) 
show a negative correlation between cyclin E expression and positive patient outcome, giving an 
effective diagnostic tool for evaluating cancer prognosis. Keyomarsi et al. (2002) found that 
patients with early stage breast cancers with high cyclin E expression all died within five years of 
diagnosis (12/12), while similar patients with low cyclin E expression all survived the five year 
mark (102/102). It has been shown, however, that cyclin E production is not directly correlated 
with speed of cancer growth in patients (Hwang & Clurman 2005).  
 What should also be noted is that CUL3 itself is regulated in many ways. Various BTB-
domain (bricabrac-tramtrack-broad complex) Kelch-like proteins function as different adaptor 
proteins to target CUL3 to the specific protein of interest (seen in Figure 2). The BTB domain 
binds to the ligase while the Kelch domain binds to the substrate (Canning et al. 2013). Without 
these adapter proteins, CUL3 is unable to bind to target proteins and thus cannot catalyze 
ubiquitin attachment (Xu et al. 2003). For example, MEL26 is an adapter protein for MEI1. A C. 
elegans embryo with a MEL26 knockout expresses the same abnormal mitotic spindle expressed 
in a CUL3 knockout embryo (Pintard et al. 2004, Xu et al. 2003). When it comes to potential 
treatment avenues, individual BTB adaptor proteins could be targeted rather than CUL3 itself to 
ensure specific and effective treatment.  
 CUL3 is also regulated on larger scales by neddylation and deneddylation – attachment 
of Nedd8 to change the conformation of CUL3 and affect its function (Parry and Estelle 2004). 
While in reference to a CUL3 knockout neddylation patterns shouldn’t affect much, 
overexpression of CUL3 would be more susceptible to Nedd8 alteration (see Figure 2). 
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CUL3’s Role in Cancer 
 While CUL3 was implicated in murine lung cancer by Dr. Starr, the link of CUL3 to 
colorectal cancer is relatively unknown. The COSMIC (Catalogue of somatic mutations in 
cancer) database has one entry regarding colon cancer and CUL3, although it does have 34 listed 
entries that corroborate CUL3 as a general cancer driver gene (most of this information comes 
from unpublished data dumps, including the data regarding the gene’s involvement in colon 
cancer).   
 An effective method of determining the role of a gene to cancer is to perform a knockout. 
This essentially mutates a gene to the point where the protein product is no longer functional. 
With a CUL3 knockout cell line, we may be able to evaluate CUL3’s importance to cancer in a 
more meaningful way. A new method of performing a knockout (and the one used in this study) 
is the CRISPR/Cas9 system. 
 
CRISPR/CAS9 AND GENE KNOCKOUT 
The Discovery of CRISPR/Cas9 
 The CRISPR/Cas9 system was originally discovered in archaea and bacteria, which use 
the system as a defense mechanism against invading viral DNA and plasmids. It has been most 
extensively studied in the bacterial species Streptococcus pyogenes. Jinek et al. (2012) proposed 
its utilization as a biotechnological tool for DNA editing, as it is easily programmable and very 
specific. 
 In the single-cell organisms from which this system was derived, the viral DNA is 
integrated into the organism’s own genome to target that same virus at the next instance of 
infection. Once the invading DNA enters the cell, it gets fragmented into protospacers which are 
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then integrated into the CRISPR (clustered regularly interspaced short palindromic repeats) array 
so that they come directly after the repeat sequence (Jinek et al. 2012). The cell now has multiple 
recognition sequences (spacers) targeting known invasive DNA, which can direct DNA silencing 
with Cas (CRISPR-associated) cutting enzymes (Figure 5). At the next instance of viral invasion, 
the Cas enzymes and the multiple 
spacer/repeat sequences, or crRNAs will be 
transcribed. The Cas enzymes, after 
translation, will align with the crRNA and 
the complex will meet the viral invader. If 
the crRNA sequence aligns with the viral 
DNA, the Cas enzymes will catalyze a blunt 
cut, inactivating the viral DNA and 
allowing its digestion by other nucleases 
(Jinek et al. 2012, Mali et al. 2013, Ran et 
al. 2013).  
While there are three types of CRISPR/Cas systems, the type II system has been the 
subject of further study with regards to biotechnological use. This is due to the fact that it 
requires only one Cas protein - specifically Cas9 - instead of a multi-Cas protein complex, like 
types I and III. In types I and III, the raw crRNA is altered by one Cas protein, and cleavage is 
caused by multiple other Cas proteins formed into a complex. Type II requires only one Cas 
enzyme (Cas9) because of the utilization of a second RNA, a trans-activating crRNA, or 
tracrRNA, that base pairs to the repeat sequence of the crRNA (Jinek et al. 2012).  
Figure 5. Diagram of CRISPR array and protospacer insertion in 
bacteria. (Adapted from Kyoto University Laboratory of Bacterial 
Infection) (Proto)spacers are integrated into a bacterial genome to 
directly follow the CRISPR repeat sequences. 
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The bacteria also avoid cleaving its own DNA by a very specific recognition system. It 
involves the protospacer’s placement within the invasive DNA relative to a short specific 
nucleotide sequence, known as the PAM, or protospacer adjacent motif. For S. pyogenes, this 
sequence is NGG, placed three nucleotides upstream of the protospacer within the invasive DNA 
(Jinek et al. 2012).  
The Use of CRISPR/Cas9 for Gene Knockout 
 The CRISPR/Cas9 system has become increasingly popular as a method of genome 
editing. It has all but replaced zinc-finger nucleases (ZFNs) and transcription activator-like 
effector nucleases (TALENs) as the go-to system for genome editing and gene knockout. These 
two systems have similar endonuclease activity to CRISPR/Cas9, but they take longer to make 
and are less effective overall. From start to finish, a CRISPR/Cas9 knockout can take only a 
month to complete (Ran et al. 2013). This study took two months.  
 To use the CRISPR/Cas9 system, certain changes needed to be made to the bacteria’s 
system. The most obvious was to place the important pieces into a vector to place it into desired 
cells. Two options currently exist: one is plasmid vectors that are transfected into the organism of 
choice, and the other is a viral vector. Lentivirus is preferred here, as it can infect live hosts and 
dividing cells, ideal for animal modeling. Additionally the crRNA and tracrRNA portions were 
fused by a hairpin loop, making one long single guide RNA, or sgRNA, which only requires one 
template (Jinek et al. 2012; Hwang et al. 2013). The beauty of the CRISPR/Cas system is its 
genetic brevity, making vector transfection rather simple.  
Lastly, targeting to the gene of interest is needed. This involves finding an approximately 
20 bp section (protospacer) within the mRNA of the desired gene that is three base pairs 
downstream of a specific PAM sequence (Figure 6). The number of base pairs between the 
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protospacer and the PAM and 
the exact PAM sequence is 
dependent on the organism of 
derivation of the sgRNA and 
the Cas9 enzyme, as they vary 
from species to species (Jinek et 
al. 2012). After the target 
sequence is chosen, this 
sequence is added to the 5’ end 
of the sgRNA template to create 
the spacer. The spacer is the only portion of the entire CRISPR/Cas9 complex that changes from 
target to target (Jinek et al. 2012; Mail et al. 2013). Depending on the target cells, whether they 
are human or mouse or other, the Cas9 enzyme coding sequence is often altered to optimize for 
the codons commonly used in the organism of interest. Additionally, human (or other 
organism’s) promoters are used at the beginning of the Cas9 and the sgRNA sequences to ensure 
constitutive expression once within the cells. For example the human U6 polymerase III 
promoter is commonly used in front of the sgRNA when transfecting human cell lines in vitro 
(Mali et al. 2013).  
 Once the cells have been transfected, either by viral vector or plasmid (as was used in this 
study), the system uses the cell’s own internal machinery to transcribe the Cas9 enzyme and the 
sgRNA, aided by the humanized promoters. The Cas9 enzyme associates with the crRNA and 
tracrRNA domains of the sgRNA. The Cas/sgRNA complex then aligns with the protospacer and 
the PAM sequence while holding apart the two strands of the target DNA. The Cas9 enzyme 
Figure 6. Configuration of sgRNA and Cas9 with genomic DNA. (Hwang et 
al. 2013; Used with permissions from the Nature Publishing Group) Above 
shows the structure of the sgRNA and how it targets within the genome. Note 
the PAM sequence NGG directly downstream of the target site. 
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then catalyzes cleavage of each individual strand of the DNA. Hopefully, this cleavage will 
result in a mutation when rejoined by non-homologous end joining (NHEJ) (Ran et al. 2013). 
NHEJ is used when both DNA strands are cut and a DNA template for the region is unavailable. 
It involves the recruitment of various capping proteins that bring the two ends together and a 
ligase (ligase IV) to reconnect the strands. It often results in frameshift mutation, as some 
nucleotides can be lost during DNA cleavage or inserted in the repair process (van Gent & van 
der Burg 2007).  
If mutation does not occur during DNA repair, the system will repeat the process, as long 
as the spacer can still recognize the protospacer (Hsu et al. 2013). This process also ensures 
DNA mutation as long as the templates for both the Cas9 enzyme and the sgRNA plasmids were 
successfully transfected into the cell. 
Off-Target Effects 
 While the system is specific and efficient, there is also the possibility of off-target effects, 
as there are with any nuclease. The number of off-target sites and the frequency of off-target 
cutting is dependent on the sgRNA sequence chosen. Obviously if the target sequence exists in 
more than one place in the genome, Cas9 with catalyze cleavage at both sites about equally. Ran 
et al. (2013) found that some level of mismatch is allowed in sgRNA base pairing with its target. 
For the most part, only three or less mismatches in the 20 bp sequence, or 85% or more sequence 
homology, is tolerated. Additionally, mismatches are more tolerated at the 3’ end of the 
sequence. The frequency of mismatch base-pairing is also dependent on the concentration of 
Cas9 and sgRNA transfected into the cells, as well as their ratios. The frequency of off-target 
cutting increases as the concentration of Cas9 plasmid dosage at initial transfection increases 
(Hsu et al. 2013). 
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 The easiest way to prevent off-target effects is to carefully select the sgRNA sequence. 
Certain design databases such as ZiFiT (Sander et al. 2010) and the CRISPR Design Tool 
(http://tools.genome-engineering.org) will give the most likely off-target sites with every 
potential target sequence. However, they are still possible even with the greatest precautions and 
should therefore be analyzed in all uses of CRISPR/Cas9.  
 
PURPOSE OF STUDY 
 CUL3 has been shown to be an important driver gene in lung tumorigenesis in mice. Due 
to the implications that this gene is a general cancer driver gene, CUL3 is likely also important in 
human CRC development. CUL3 ligase has many different known substrates – some of which 
may have effects on cell health and cancer proliferation. We have attempted to evaluate the 
importance of CUL3 to human CRC using CRISPR/Cas9 based CUL3 knockout in the HCT-116 
human colorectal cancer cell.  
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METHODS 
Cell Culture 
 HCT-116 cells were cultured at 37° C and 5% CO2 in DMEM (Dulbecco’s Modified 
Eagle Medium) (Gibco, Grand Island NY), supplemented with 1% L-Glutamine (Gibco, Grand 
Island NY), 1% Penicillin/Streptomycin/Fungizone (PSF) (Gibco, Grand Island NY), 2.5% 
HEPES buffer (Gibco, Grand Island NY), and 10% Fetal Bovine Serum (FBS). Cells were stored 
frozen in FBS containing 10% DMSO (Dimethyl sulfoxide) (Sigma-Aldrich, St. Louis MO) and 
cryopreserved in liquid nitrogen until needed. When cells were passed, they were first removed 
from culture flasks by treatment with 0.5% Trypsin-EDTA (Gibco, Grand Island NY) for 10 
minutes. After trypsin neutralization, they were diluted 1:20 in their new flask, unless an 
abnormal (slowed) growth phenotype was seen, in which case they were passed 1:10.  
Puromycin Assay 
The HCT-116 cells were plated at a 1:10 dilution in a 96-well plate and allowed to grow 
up for three days. After the cells had reached 80-90% confluence, the media of some wells was 
removed and replaced with puromycin media at various concentrations of puromycin: 10 ug/mL, 
5 ug/mL, 2.5 ug/mL, 1.25 ug/mL, .625 ug/mL and 0 ug/mL. Four replicates of each 
concentration were created in the plate. Every 24 hours after the initial media replacement, one 
well of each concentration was removed and counted by trypan blue exclusion. At the end of 
three days, the minimum concentration that produced complete death was chosen. In this 
experiment, 1 ug/mL of puromycin was chosen for subsequent selection steps. This 
concentration is consistent with the 1 ug/mL concentration used by Dr. Starr at the University of 
Minnesota for this cell line. 
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Lipofectamine Assay 
HCT-116 cells were plated in a 24-well plate and allowed to grow until at 60-70% 
confluence, or about two days. After confluence had been achieved, the cells were transfected 
with two plasmids: the Piggy-BAC puromycin resistance plasmid and the pB7 transposase 
plasmid. To determine the ideal concentration of the transfection chemical, Lipofectamine 
(Invitrogen, Carlsbad CA), the cells were transfected with varying concentrations (1uL, 1.5 uL, 
2uL, and 2.5 uL/mL media) of Lipofectamine. Each well was given .25 mg of each plasmid per 
mL. Prior to transfection, the plasmids and Lipofectamine incubated in OptiMEM media for 5 
minutes to ensure full coating of the plasmids in the Lipofectamine. The Lipofectamine-plasmid 
complex was then added to the media of 2 wells (per concentration) of the 24-well plate (see 
Appendix 5). After the addition of the Lipofectamine-plasmid complex, the cells were allowed to 
recuperate and grow for 24 hours. This also allowed enough time for the cells to take up the 
antibiotic resistance plasmids and become puromycin-resistant. After this 24 hour period, the 
media of the transfected cells was replaced with media containing puromycin at the 
predetermined 1 ug/mL concentration. The cells were allowed to sit in the puromycin for four 
days undisturbed. After this 4 day period, the cells were analyzed for overall confluency. 
Optimal Lipofectamine dilution was chosen based on which concentration produced the highest 
number of transfected (puromycin resistant) cells. 
Confluency Assay 
HCT-116 cells were plated in 4-well increments at varying concentrations ranging from 
100-5000 cells per well. They were allowed to grow up for four days. After this time, overall 
confluency was recorded. The lowest concentration that resulted in an average of approximately 
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90% confluency was determined to be optimum. For HCT-116, this was approximately 2500 
cells per well. 
U6-sgRNA Plasmid Design 
 Plasmid design was performed by Dr. Goldberg’s lab in the summer of 2013. The empty 
U6-sgRNA plasmids (without a target sequence introduced) were obtained from Dr. Starr at the 
University of Minnesota. Inverse primer design was performed using the ZiFiT computer 
program, which locates multiple target sequences within the target gene that also has the PAM 
sequence directly after the target DNA (Sander et al. 2010). In this study, the CRISPR/Cas9 
system was derived from S. pyogenes, making the PAM sequence NGG. The plasmids were 
created using Inverse PCR and frozen in nuclease-free water at -20° C until use in 2014.  
CRISPR/Cas9 Knockout 
HCT-116 cells were plated in a 24-well plate and allowed to grow two days until they 
reached 60-70% confluency. After this time, the cells were transfected using the predetermined 
Lipofectamine concentration. Four plasmids were placed in each well: the Piggy-BAC 
transposon with puromycin resistance, the pB7 transposase plasmid, the Cas9 endonuclease 
plasmid, and the pU6 RNA guide sequence. Three different U6 guide sequences were created 
previously to target the CUL3 gene. Two wells of the 24-well plate were transfected for each 
pU6 plasmid. The Piggy-BAC and pB7 were still at 0.25 ug per well, but the Cas9 and the pU6 
were added at 1 ug per well in an effort to ensure that every colony that received antibiotic 
resistance would also likely have the knockout. After Lipofectamine-plasmid complex 
incubation, the wells were transfected and allowed to grow up an additional 24 hours before 
subcloning. 
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Subcloning 
24 hours after transfection, the transfected cells were removed from the 24-well plate and 
replated in 96-wells in 1 ug/mL puromycin media at low density (2000-3000 cells per well), 
determined by the confluency assay. After 8 days of incubation with puromycin media, clonal 
colonies were selected by locating wells with a single colony that had arisen from a single cell. 
Over the next month, selected cell lines were removed from their wells when appropriate (60-
70% confluency) using 0.5% Trypsin-EDTA incubated for 5-15 minutes. They were placed into 
a larger culture container until they could maintain normal growth in a 25 mL culture flask. At 
this point, cells were partitioned off for DNA extraction and freezing. 
Imaging 
 All images were captured with an inverted light microscope set at 100x connected to an 
iPhone 5 (2013). Images were adjusted to improve clarity by Windows Photos (2014).  
DNA Extraction 
 DNA extraction was performed with the Promega Wizard Genomic DNA Purification Kit 
(Madison, WI). Resulting DNA purity and concentration was determined with a Nanodrop 2000. 
Primer Design and PCR 
 Primers were designed by hand using the genomic CUL3 DNA sequence from NCBI 
Blast. Primer alignment was confirmed using PrimerQuest and IDT (Integrated DNA 
Technologies) Primer Design. Primers were obtained from IDT (Coralville IA) as standard 
desalted oligos (sequences in Appendix 1).  
 PCR was performed using Gotaq Green Master Mix (Promega, Madison WI), the 
previously mentioned primers and extracted DNA to amplify the regions of intended knockout 
for sequencing as per Gotaq protocols (see Appendix 3). PCR was performed using an 
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Eppendorf Mastercycler Nexus Gradient Thermal Cycler according to manufacturer suggestions 
using the program outlined in Appendix 2.  
 Confirmation of successful PCR was done by gel electrophoresis. PCR product was run 
on a 1% agarose gel using a BioRad MiniSub® Cell GT Cell horizontal gel box and compared to 
a Bioline (Boston MA) 50 bp ladder. The gel was imaged with a BioRad GelDoc XR+ UV 
transilluminator to ascertain appropriate band length and PCR product amount.  
 PCR product was purified using the Promega SV Gel and PCR Clean-Up System 
(Madison WI). Resultant products were maintained in the provided EB buffer before sequencing.  
Sequencing and Confirming Knockout 
 Sequencing of PCR products was performed by Functional Biosciences (Madison, WI). 
The sequencing results of all cell lines created using the P1 sgRNA guide plasmid were aligned 
using ClustalW to look for genetic inconsistencies between the Ctrl (parental) sequence and the 
various transfected cell lines. Any nucleotide differences within 10 bp of the supposed target site 
from the parental HCT-116 DNA sequence was considered to be a confirmed knockout.  
MTS Assay 
 HCT-116 cells were plated at low density, previously determined by the confluency 
assay, in 12 wells of a 96-well plate, placed in 2 rows of 6 wells. Four plates per cell line were 
created to take data over a four day span. Each day, one plate was used for analysis. 6 of the 12 
wells per cell line had 20 uL of Promega AQueous ONE CellTiter MTS Liquid (Madison, WI) 
added, and all used plates were placed back into the incubator for four hours to allow 
colorimetric development. The 12 wells were measured with a plate reader at both 490 nm and 
650 nm. This process was repeated for four straight days to determine changes in metabolic rate 
over time. 
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Off-Target Sites 
 Potential sites of off-target cutting for Cas9 construct #1 were determined using an NCBI 
Blast search for the primer and PAM sequence. The PAM sequence used was both NGG and 
NAG, as Hsu et al. found that both PAMs can be recognized for off-target cutting (2013). Any 
result below 80% homology was also excluded based on Hsu et al.’s findings.  
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RESULTS 
Various Experimental Assays 
As the mutant cells should carry puromycin resistance after transfection, an ideal 
concentration of puromycin, one that would allow complete death of all non-resistant cells (e.g. 
non-transfected cells) in 4 days, with the lowest concentration possible to avoid damaging the 
mutant cells, was required. This was determined by exposing wells of HCT 116 to varying 
concentrations of puromycin and recording the percent viability daily for three days. As shown, a 
concentration of 1.25 ug/mL or above of puromycin is ideal to see total death after three days 
(Figure 7). This study required four or more days in puromycin, though the data was taken over 
three days. As 1.25 ug/mL was effective after three days, and 0.625 ug/mL showed little-to-no 
change after three days, our results were in the range of the Starr lab’s experimentally 
determined value of 1 ug/mL, which was used in further experiments.  
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Figure 7. Percent Viability of Cells based on Puromycin Concentration. Percent viability was determined over 3 
days by trypan blue exclusion. A concentration that produced total death after four days is ideal. 
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 The ideal concentration of lipofectamine, the chemical used in transfection, was 
determined by transfecting CRC cells at varying concentrations of lipofectamine and the 
puromycin resistance plasmids, and then subsequently incubated in the previously determined 
puromycin concentration. A concentration too low would not allow all transfection possible and 
a concentration too high could prove toxic to the cell. This assay was performed not only with 
HCT-116, the cell line used in this study, but with DLD-1 and HT-29 as well, two other CRC 
cell lines that, in the future, may also be 
mutated and evaluated (Figure 8). As shown, 
a lipofectamine concentration of 1.5 uL/mL 
media was determined to be ideal for all 
three cell lines. For HCT-116, Figure 9 
shows the raw confluency and number of 
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Figure 8. Lipofectamine Assay. Three colorectal cancer cell lines were transfected with puromycin antibiotic 
resistance plasmids with varying concentrations of Lipofectamine. After four days of treatment with puromycin, 
the confluency of the treated wells was determined. 
Figure 9. HCT-116 Lipofectamine Assay results. Results were 
taken on Day 4 of the assay. In red, confluency of the well is 
shown. In blue, the number of individual colonies is shown. 
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colonies data four days post transfection and puromycin treatment.  
 To ensure the cells 
were plated at a low 
enough concentration to 
achieve the desired one-
living-cell-per-well ideally 
needed to create individual 
clonal cell lines, a 
confluency assay was 
performed. The goal was to 
determine the concentration 
of cells that would take 
four days to achieve a confluency of 85-90% (Results in Figure 10). Cells were plated at initial 
concentrations varying from 100-5000 cells per well in a 96-well plate. A 96-well plate was used 
because that was the plate to be used to start our clonal colonies. After four days of growth at 
varying concentrations, the ideal concentration chosen was between 2000 to 3000 cells. Previous 
plating attempts showed that a concentration closer to 3000 cells/well was too concentrated to 
produce single clonal colonies in one well at a high enough frequency, so for our purposes, 
transfected cells were plated at an initial concentration closer to 2000 cells/well. Anecdotally, 
nearly all wells found to have any living cells contained single clonal colonies, with only a 
handful of  wells containing two or three colonies. The 41 cell lines obtained were from 6 plates 
(or 576 total wells), and no single clonal colony was left out.  
 
Figure 8. Confluency assay results of HCT-116. Cells were plated at varying 
concentrations (100-5000 cells/well) and grown for four days. The above results 
show the approximate confluency in that time. For HCT-116, approximately 
2500 (or 2000-3000) cells per well achieved an ideal confluency (approximately 
85-90%) after four days. 
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Observational Data 
 10 days post-transfection and puromycin treatment, individual clonal cell lines were 
selected and evaluated. Speed of growth was ascertained by approximate colony size after 10 
days and categorized into four categories: Fast, Medium, Slow, and Super Slow. Those cell lines 
categorized as Fast and Medium were transferred to a 24-well plate to allow further growth. 
Slow speed cell lines were transferred 7 days later (17 days post-transfection), and Super Slow 
speed cell lines were transferred 2 days after that (19 days post-transfection).  
 Once the cells were 
transferred to culture flasks, the 
growth speed as a measure of 
frequency of passage was taken. 
The parental cell line (with all 
cell lines normalized to its rate of 
passage) was seen to have a 
passage rate of half or less than 
the passage rate of any knockout 
Cell Line 
Growth Speed 
(approximate) 
Abnormal 
Morphology? 
Extra-Large 
Cells 
Abnormal 
Adherance 
Parental Fast No   
1MY1 Medium Yes  * 
1MY2 Medium Yes  * 
1SY1 Slow Yes +  
1SY2 Slow Yes +  
1SY5 Slow Yes +  
1SSY2 Super Slow Yes +  
Table 1. Parental and confirmed knockout cell line observational data. Cell lines are categorized at various 
growth speeds and whether or not they exhibited abnormal morphology. 
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Figure 9. Comparison of passage rates for parental and knockout cell lines. 
The cells were passed at a frequency relative to their growth speed and the rate 
at which they ran out of culture flask surface space. The fewer days between 
passes, the faster the cells grow. All data is normalized to the ratio of passage.  
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cell line, which indicated that it grew at twice (or more) the speed of the knockouts (Figure 11).  
Further evaluation while the cells continued growing was done based on approximate size 
of cells and adherence to the cell culture surfaces. Of the 14 cell lines categorized as Fast (within 
all three sgRNA constructs), no cell line exhibited any abnormal morphology. These cell lines 
Figure 10. Phenotypic differences between cell lines. HCT-116 (A) shows parental cell line 
growth, 1MY2 (B) shows abnormal cell flask adherence, and 1SY5 (C) and 1SY1 (D) display 
abnormally sized cells. All images were taken at 100x.  
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also grew at the approximate speed of the parental cell line in all culture container types (96-
well, 24-well, 6-well, and flask). 8 of 11 Medium speed cell lines exhibited abnormal 
phenotypes, with 7 of 8 exhibiting abnormal adherence (5 less adhered, 2 more adhered), and 3 
of 8 exhibiting extra-large cells among the normal sized cells (as compared to the parental cell 
line) (Examples in Figure 12). The 13 cell lines exhibiting Slow growth speed all exhibited some 
sort of abnormal phenotype. 10 of the 13 exhibited extra-large cell sizes and 6 of the 13 
demonstrate differing surface adherence (3 less and 3 more adhered). All 4 Super Slow cell lines 
exhibited expanded cell size. It should be noted that, depending on the degree of largeness seen 
in the cells, and the percentage of cells with this affliction could potentially interfere with visual 
flask adherence observations, due to sheer inexperience with this type of cell.  
Determining Knockout 
 PCR program and 
primers were confirmed 
to work by gel 
electrophoresis (Figure 
13). The gel also 
demonstrated that the 
PCR product was ample 
for sequencing (based on 
band brightness) and 
relatively pure. 
 Knockout was suspected in all cells containing an abnormal phenotype and not suspected 
in cell lines that did not exhibit the abnormal phenotype. As a result, only one cell line in the Fast 
   1.1       1.2         2.12 2.21   3.1     Ladder 
388 
bp
459 
bp319 
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295 
bp
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Figure 11. Confirmation of desired PCR product. Primers used to amplify the 
region of intended knockout were used on genomic HCT-116 DNA to ensure 
ample PCR product at the intended length in base pairs. Assumed length is above 
each band, and ladder band values are underlined in red. Primer sets (above their 
respective lanes) can be found in Appendix 1. 
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growth category was evaluated for knockout. As stated, PCR was only performed in the area of 
attempted knockout – three different areas for the three different sgRNA constructs. As knockout 
was only able to be confirmed in six cell lines, all transfected with sgRNA construct #1, those 
results are shown, compared to the one Fast cell line, the parental cell line, and the one cell line 
that does not contain a knockout, 1SSY1. Knockout was obtained in all confirmed cell lines by 
way of frameshift, or indel, mutation. All cell lines show some sort of insert, and three of the six 
also show some sort of deletion (Figure 14).  
 Due to frameshift mutation in all cell lines except 1MY2, the protein product derived 
from the mutant CUL3 mRNA is expected to be largely inaccurate, potentially creating a 
premature STOP codon and translating all amino acids after the site of mutation in the wrong 
open reading frame. 1MY2 would result in the addition of an amino acid to the sequence, which 
could affect protein folding or interactions of the ligase with other proteins.  
Changes in Metabolic Activity 
 MTS is an altered, more accurate form of the MTT assay (both named for the type of 
tetrazolium salt used). This assay measures metabolic activity, and therefore cell growth and 
survival, by the conversion of tetrazolium salt to formazan. This change is catalyzed by the 
Figure 12. Alignment of sequencing results of confirmed knockouts. Six cell lines (1SY1, 1SY2, 1SY5, 1SSY2, 
1MY1, 1MY2) have confirmed knockouts by way of frameshift mutation (highlighted in blue), 1SSY1 can be 
confirmed to have no knockout at this location, and knockout in 1FN1 is unable to be determined. 
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mitochondrial enzyme succinate dehydrogenase, which cleaves the salt to form formazan. The 
cleavage results in a color change that is then read by a spectrophotometer (Buttke et al. 1993, 
Denizot and Lang 1986).  
 Preliminary data (resulting from one run of the assay) suggests that CUL3 knockout has 
resulted in an increase in metabolic activity (Figure 15). All cell lines with a confirmed knockout 
had significantly higher formazan output than the parental cell line for the first two days. By the 
fourth day, the parental cell line had caught up to the knockouts, indicating that all cell lines may 
have tapered off in metabolic activity increase. This is usually the result of reaching spatial 
constraints and commonly seen in the parental cell line.  
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Off-Target Effects 
 An NCBI Blast search for the target sequence and PAM (both NGG and NAG) was 
performed to locate sites within the human genome that may be targets of off-target cutting. The 
Blast search resulted in five potential off-target cut sites in actual genes. Two other sites were 
found in non-coding regions of the genome (Figure 16). Of the five potentially deleterious off-
target sites, only one had homology of over 90% to the original target sequence. Two had over 
85% homology, but both had the NAG PAM, indicating that they might be less likely to bind 
than a NGG counterpart.  
 
 
 
 
 
 
 
  
Figure 14. Possible Off-Target Effects. The potential off target sequences compared to the P1 CUL3 
target sequence used in the sgRNA CRISPR. NC1 & 2 are non-coding regions, RAVER2 is 
Ribonucleotide PTB-binding 2, PEX1 is Peroxisomal biogenesis factor 1, LRPPRC is Leucine-rich PPR 
motif containing protein, BBX is an HMG box transcription factor, and FOX1 is Forkhead box protein 1.  
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DISCUSSION 
EXPERIMENTAL FINDINGS 
Morphological Changes 
 In every cell line with a confirmed knockout, morphological changes were seen. While 
the specific changes vary from cell line to cell line, the majority of cell lines with confirmed 
knockout exhibit a phenotype that would be expected of a CUL3 knockout.  
 The morphology seen could be due to CUL3’s effects on monoubiquitination of Aurora B 
kinase, an enzyme involved in mitotic spindle stability and cytokinesis. Because of the function 
of monoubiquitination as a modulator of protein function and localization (as opposed to 
degradation targeted by 
polyubiquitination), a CUL3 
knockout essentially results in 
knockout of Aurora B’s 
secondary function and 
localization (Maerki et al. 
2010, Sumara et al. 2007). 
Sumara et al.’s results using 
RNAi to inhibit CUL3 
translation best exemplifies visually the resultant multinucleation and inhibited cytokinesis, seen 
in Fig. 17 (2007). The mechanism by which this is occurring is elucidated by Maerki et al. (2009, 
2010), where they posit a role for Aurora B monoubiquitination in aligning chromosomes to the 
divisional plane. Aurora B degradation, similar to inactivation, has been shown to result in faulty 
cytokinesis and multinucleation. Additionally, there is evidence that inhibition of normal Aurora 
Figure 15. Multinucleation due to CUL3 knockdown. (Sumara et al. 2007; 
Used with permissions from Elsevier) RNAi that inhibits CUL3 function 
results in multinucleated cells due to interference with normal Aurora B 
function. 
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B activity results in excess microtubule formation, increasing especially astrally (from the 
centrosome but not connecting to a kinetochore) (Figure 4) (Kallio et al. 2002).  
 Because multinucleation and failed cytokinesis halts the cell cycle, Aurora B inhibition 
could also be seen to slow the overall growth rate of a cell culture, which may explain the need 
for less frequent passage in the knockout cell lines. We expect that if Aurora B was completely 
inhibited, no cytokinsese would occur and the cells would not survive. However, though Aurora 
B monoubiquitination is critical for cytokinesis and its inhibition, in all literature reviewed, it 
does not seem to effect all cells in the culture identically. In this way, CUL3 knockout to disable 
Aurora B monoubiquitination is more similar to a knockdown of Aurora B monoubiquitination. 
This means that Aurora B function is severely inhibited, but not completely gone, allowing some 
cells to survive and reproduce.  
Metabolic Activity 
 The MTS assay used in this study is traditionally used as a method of ascertaining 
proliferation of cells. Changes in metabolic activity can easily be correlated with changes in cell 
growth in culture. This is assuming a relatively homogenized culture, with cells with equivalent 
ATP requirements and mitochondrial output. However, if a mutation causes abnormal metabolic 
activity, this assay no longer accurately measures the number and rate of cell proliferation.  
 Due to time constraints, the MTS assay had only one trial, with six individual wells 
measured per cell line. Given that only one assay was performed, this assay will need to be 
replicated to determine if the effects seen are reproducible. The trends here indicate that 
metabolic activity increases in knockout cell lines, but one trial gives the conclusions drawn little 
confidence. Therefore the first step before any concrete conclusions are drawn would be to rerun 
the assay to the point where statistics can be run.  
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 None of the afore-mentioned substrates of CUL3 give an ideal explanation for why 
CUL3 knockout cells would suddenly have higher metabolic activity. Likely, if the effects are 
due to the knockout, the substrate responsible for increased metabolic activity has yet to be 
discovered. There is also the possibility that the abnormal metabolic activity is due to off-target 
Cas9 cutting.  
Off-Target Effects 
 As previously stated, occasional off-target effects are unavoidable. Sequencing data of 
the 1SSY1 cell line shows that no knockout occurred at the expected site. However, this cell line 
still exhibited abnormal morphology and a substantially slowed growth rate (anecdotally). This 
cell line is the most likely candidate for off-target cleavage. Of the seven off-target sites 
identified in Figure 16, only four fit the criteria outlined by Ran et al. (2013), which includes 
over 85% homology with the mutations at least 4 bp away from the PAM sequence. Only one is 
within a non-coding region of DNA. The other three, PEX1, BBX, and FOX1, are the most 
likely sites of off-target cutting, with priority to PEX1, as it retains the NGG PAM sequence and 
has a higher percent homology (91% v. 86%) to the target sequence. Further study is needed to 
determine whether or not these off-target sites are responsible for the abnormal morphology seen 
in 1SSY1, and potentially other cell lines.  
 
PERFECTING THE CUL3 KNOCKOUT 
Alterations to the Current Approach 
 The CRISPR/Cas9 system, as described in the methods portion, produced six successful 
KO-CUL3 cell lines. However, since six out of 41 total cell lines is a 14% success rate, the 
knockout efficiency could be increased with alterations to the approach.  
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Another option would be to introduce multiple protospacers within the gene of interest 
per transfection in hopes that, if one target does not work, another may do better. In the archaea 
and bacteria from which this system is derived, multiple protospacers targeting the same plasmid 
or virus will be integrated into their genomes (Jinek et al. 2012). This gives the Cas9 more target 
sequences at which to cleave and, theoretically, a more successful neutralization of the invasive 
DNA. The beauty of the Cas9 enzyme is that once the template DNA for Cas9 is in the target 
cell’s genome, the enzyme can cut anywhere, and in multiple places, as long as a crRNA 
template(s) are provided.  
Genome Editing versus Gene Silencing 
In this study, gene silencing was the goal of the transfection process - mutation in the 
gene to either shift its reading frame into nonsense or produce a premature stop codon. However, 
another option exists - gene editing. This is done very similarly to gene silencing, where 
transfection occurs, introducing the Cas9 enzyme and two sgRNA constructs, resulting in two 
double-stranded breaks and excision of the area of interest. It also requires transfection of a 
repair template, as the major difference occurs in the repair process. Where single DNA breaks 
prefers the mutation-prone NHEJ (non-homologous end joining) process, DNA excision uses 
homologous recombination. Homologous recombination uses the transfected template to repair 
the break in a guided way. This template contains the gene edits. Single nucleotide differences 
can be introduced with a single break, and large portions of the gene can be rewritten with two 
breaks (caused by two differently targeted sgRNAs) (Ran et al. 2013).   
With regards to CUL3, gene editing could be used to check the opposite of gene 
knockout - a knockin - by altering the promoter to turn the gene constitutively on. If a knockout 
results in slower growth, a knockin could result in accelerated growth. A knockin would likely 
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not demonstrate the same morphological changes seen in this study, as Aurora B function should 
be uninhibited, and potentially better. Knockin would also likely increase resistance of cells to 
CPT (camptothecin chemotherapy) by decreasing cellular TOP1 concentration.  
Temporary CUL3 Knockout 
 The use of a catalytically inactive Cas9 has been seen to create a reversible knockout, or 
knockdown. The Cas9 still targets the gene of interest by way of sgRNA guidance, but instead of 
catalyzing a double-stranded break, the Cas9 will bind to the target site and inhibit transcription 
by simply getting in the way. Because no permanent mutation has occurred, the process, called 
CRISPRi, is reversible (Qi et al. 2013). This could allow the researcher to inhibit CUL3, and 
then remove the inhibition to see if the various phenotypes rectify themselves.  
 
CUL3’S KNOWN ROLE IN CANCER 
Database Results 
 CUL3 itself has been implicated as a driver gene in several types of human cancers, 
including head and neck squamous cell carcinoma; lung, stomach, and prostate adenocarcinoma; 
cutaneous melanoma; and esophageal carcinoma. In all cancers, the driver mutation resulted in a 
loss of function of CUL3 (IntOGen). Many of the mutations (72.5%, according to COSMIC) 
catalogued both by IntOGen and COSMIC result in a missense substitution mutation within the 
CUL3 gene. In addition to missense mutations of the gene itself, mutation in the neddylation 
protein Nedd8 has been found to affect cancer by way of controlling CUL3 function (IntOGen). 
The frequency of CUL3/Nedd8 mutation in any of the experiments reporting CUL3/Nedd8 
mutation was no more than 3-4% of the genotyped cancers. While CUL3 does seem to have a 
role in driving cancer, it does so at a relatively infrequent rate. 
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 IntOGen does not classify CUL3 as a driver gene for colorectal cancer. It does, however, 
reference the data found in COSMIC indicating that CUL3 is known to mutate in CRC. While 
the status of CUL3 as a driver gene in cancer is weak, CUL3 is still an intriguing therapeutic 
target and diagnostic tool. 
Cancer Treatments 
 Substrates of CUL3 have been linked to the effectiveness of certain types of 
chemotherapies, giving CUL3 knockout cancers certain properties. CUL3 knockout makes it less 
likely that an individual will acquire resistance to antitumor camptothecins (CPTs), a type of 
chemotherapy. Sometimes, a cancer cell will become resistant to CPTs by down-regulating the 
expression of topoisomerase I (TOP1), the target of the drug. This is sometimes done by 
upregulating CUL3 and the ubiquitin-based degradation of TOP1 (Zhang et al. 2004B). Studies 
have shown that ubiquitination of TOP1 is an important determinant in CPT sensitivity (Beretta 
et al. 2013). This implies that inhibition of TOP1 degradation may be able to restore CPT 
sensitivity to resistant cancers. CUL3 knockout inhibits TOP1 degradation by removing the 
machinery to ubiquinate the TOP1, thus providing us with a potential avenue for rectifying CPT 
resistance.  
 Cyclin E cellular concentration has been inversely correlated with breast cancer patient 
survivability (Keyomarsi et al. 2002). Since cyclin E production is not really tissue specific, the 
likelihood is high that colon cancers would demonstrate the same trends seen in breast cancer. 
This indicates that a CUL3 knockout in colon cancer, which increases the cellular cyclin E by 
not degrading it, will likely result in more aggressive cancers and higher overall lethality.  
 Aurora B kinase overexpression has been recently correlated with lung cancer lethality 
(Takeshita et al. 2012). Again, Aurora B expression is also not tissue-specific, making the trends 
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seen in lung cancer likely to be seen in CRC. Aurora B overexpression is correlated with 
aneuploidy, or abnormal numbers of chromosomes, which often leads to increased malignancy 
(Masafumi et al. 2012). By inhibiting Aurora B chromosomal localization by CUL3 knockout, an 
Aurora B overexpression could be rectified.  
 Nrf2 expression has very recently been linked to gastric cancer and patient survivability. 
The higher the expression of Nrf2, the more aggressive the cancer (Kawasaki et al. 2015). In 
non-small-cell lung cancer, diallelic inactivation of KEAP1 (Nrf2’s adapter protein), and 
therefore inhibition of Nrf2 degradation, results in higher rates of chemoresistance (Singh et al. 
2006). A CUL3 knockout would increase expression of Nrf2, which should make the cancer 
more aggressive overall, and more resistant to oxidative stress. CUL3 overexpression has 
conversely been seen to decrease Nrf2 expression and increase breast cancer sensitivity to 
oxidative stress and chemotherapies (Loignon et al. 2009). In this way, CUL3 overexpression 
might become a therapeutic tool.  
 There is also the potential for utilizing the CUL3 ubiquitination mechanism as a type of 
target. For example, to ensure overexpression of a gene, like TOP1, one would only need to 
inhibit its adapter protein to turn off its degradation and increase cellular concentrations of TOP1 
(Unfortunately, the adapter protein of TOP1 is as of yet undiscovered). CUL3’s many substrates 
have different effects regarding cancer growth, many of which are contradictory to one another 
when it comes to cancer growth and patient survivability. Therefore, CUL3 is likely not a good 
target for cancer treatment, but rather its individual substrates are. 
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APPENDIX 
Appendix 1. Primer Sequences 
Primer Name: Sequence 
CUL3Exon4P1.1F aagttgcacattgcttaagatc 
CUL3Exon4P1.1R cctttccgctctcttgcaatc 
CUL3Exon4P1.2F atgctcacaagaactgtactc 
CUL3Exon4P1.2R ccaatgtgctcaacattcaaac 
CUL3Exon11P2.1F gagatcgtgccattgcattc 
CUL3Exon11P2.1R ggaaattgctgtatgccagg 
CUL3Exon11P2.2F caacgagcgaaactctgtc 
CUL3Exon11P2.2R gctccttttgatcacgagg 
CUL3Exon14P3.1F ggagcccattagtttgagac 
CUL3Exon14P3.1R catctggaaagtggaaacttg 
 
Appendix 2. PCR Program 
2 minutes 45 seconds 45 seconds 30 seconds 5 minutes 
95°C 95°C 50°C 73°C 73°C 
 
 
Appendix 3. Raw Observational Data 
 
Cell Line 
Guide 
Sequence 
Growth Speed 
(approximate) 
Abnormal 
Morphology? 
Extra-Large 
Cells 
Abnormal 
Adherence 
Parental None Fast No   
1FN1 C1 Fast No   
1FN2 C1 Fast No   
1FN3 C1 Fast No   
1FN4 C1 Fast No   
1MN1 C1 Medium No   
25 cycles 
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1MY1 C1 Medium Yes  X 
1MY2 C1 Medium Yes  X 
1SY1 C1 Slow Yes X  
1SY2 C1 Slow Yes X  
1SY3 C1 Slow Yes  X 
1SY4 C1 Slow Yes X  
1SY5 C1 Slow Yes X  
1SY6 C1 Slow Yes X X 
1SSY1 C1 Super Slow Yes X  
1SSY2 C1 Super Slow Yes X  
1SSY3 C1 Super Slow Yes X  
2FN1 C2 Fast No   
2FN2 C2 Fast No   
2FN3 C2 Fast No   
2FN4 C2 Fast No   
2FN5 C2 Fast No   
2MN1 C2 Medium No   
2MY1 C2 Medium Yes  X 
2MY2 C2 Medium Yes  X 
2SY1 C2 Slow Yes X X 
2SY2 C2 Slow Yes X  
2SY3 C2 Slow Yes  X 
2SSY1 C2 Super Slow Yes X  
3FN1 C3 Fast No   
3FN2 C3 Fast No   
3FN3 C3 Fast No   
3FN4 C3 Fast No   
3FN5 C3 Fast No   
3MN1 C3 Medium No   
3MY1 C3 Medium Yes  X 
3MN2 C3 Medium Yes X  
3MY2 C3 Medium Yes X X 
3MY3 C3 Medium Yes X X 
3SY3 C3 Slow Yes  X 
3SY4 C3 Slow Yes X  
3SY1 C3 Slow Yes X X 
3SY2 C3 Slow Yes X  
 
Table 2. Raw Data on Growth Speed and Abnormal Morphology. Represented above is the categorization 
of individual cell lines from subcloning. Cell lines were assessed for relative growth speed, abnormal cell 
size, and abnormal flask adherence (either over-adhered or under-adhered). 
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Appendix 4. GoTaq Green Mastermix Protocols (Provided by Promega) 
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Appendix 5. Lipofectamine Protocols (Provided by Invitrogen) 
 
